FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2022973635> ?p ?o ?g. }

• W2022973635 endingPage "287" @default.
• W2022973635 startingPage "287" @default.
• W2022973635 abstract "We conducted a phase II study of docetaxel and ifosfamide chemotherapy for patients with platinum-resistant or refractory non-small-cell lung cancer (NSCLC) to evaluate the response and toxicity profiles as a salvage treatment.Between July 2000 and July 2004, 40 patients who had previously received platinum-based regimen as the first-line or second-line therapy were enrolled in this study. The treatment consisted of a docetaxel 75 mg/m(2) intravenous infusion on day 1 and intravenous ifosfamide 3 g/m(2) with Mesna uroprotectione on day 1 through 3. This regimen was repeated every 3 weeks.One hundred thirty cycles of treatment were given, with a median of 3 cycles (range: 2 approximately 6 cycles). All the patients were evaluable for the response rate and toxicity profile. The major toxicity was myelosuppression. Grade 3 approximately 4 neutropenia occurred in 30 patients (75%) during treatment. Febrile neutropenia occurred in 16 patients (40%). Five of 40 patients (12.5%) had a partial response (95% confidence interval, 3.3 approximately 21.7%). The median time to disease progression was 2.65 months (range: 2.02 approximately 3.20 months), and the median survival was 5.24 months (range: 2.99 approximately 7.49 months).Salvage chemotherapy with docetaxel and ifosfamide showed a low efficacy and a high proportion of severe neutropenia in patients with platinum-resistant or refractory advanced NSCLC." @default.
• W2022973635 created "2016-06-24" @default.
• W2022973635 creator A5014552930 @default.
• W2022973635 creator A5033653599 @default.
• W2022973635 creator A5039662718 @default.
• W2022973635 creator A5045806480 @default.
• W2022973635 creator A5061739989 @default.
• W2022973635 creator A5069743012 @default.
• W2022973635 creator A5070662612 @default.
• W2022973635 creator A5070988630 @default.
• W2022973635 creator A5072799823 @default.
• W2022973635 creator A5085462551 @default.
• W2022973635 date "2004-01-01" @default.
• W2022973635 modified "2023-10-18" @default.
• W2022973635 title "A Phase II Trial of Docetaxel and Ifosfamide for Patients with Platinum-Resistant or Refractory Non-Small Cell Lung Cancer in a Salvage Setting" @default.
• W2022973635 cites W1826360242 @default.
• W2022973635 cites W1839238860 @default.
• W2022973635 cites W1865725105 @default.
• W2022973635 cites W1883066466 @default.
• W2022973635 cites W1917502393 @default.
• W2022973635 cites W1967351296 @default.
• W2022973635 cites W2014184691 @default.
• W2022973635 cites W2020003033 @default.
• W2022973635 cites W2052969145 @default.
• W2022973635 cites W2058978290 @default.
• W2022973635 cites W2062811621 @default.
• W2022973635 cites W2086909567 @default.
• W2022973635 cites W2106964779 @default.
• W2022973635 cites W2114859751 @default.
• W2022973635 cites W2130652363 @default.
• W2022973635 cites W2155080317 @default.
• W2022973635 cites W2261939940 @default.
• W2022973635 cites W2263722154 @default.
• W2022973635 doi "https://doi.org/10.4143/crt.2004.36.5.287" @default.
• W2022973635 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2843870" @default.
• W2022973635 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20368817" @default.
• W2022973635 hasPublicationYear "2004" @default.
• W2022973635 type Work @default.
• W2022973635 sameAs 2022973635 @default.
• W2022973635 citedByCount "1" @default.
• W2022973635 crossrefType "journal-article" @default.
• W2022973635 hasAuthorship W2022973635A5014552930 @default.
• W2022973635 hasAuthorship W2022973635A5033653599 @default.
• W2022973635 hasAuthorship W2022973635A5039662718 @default.
• W2022973635 hasAuthorship W2022973635A5045806480 @default.
• W2022973635 hasAuthorship W2022973635A5061739989 @default.
• W2022973635 hasAuthorship W2022973635A5069743012 @default.
• W2022973635 hasAuthorship W2022973635A5070662612 @default.
• W2022973635 hasAuthorship W2022973635A5070988630 @default.
• W2022973635 hasAuthorship W2022973635A5072799823 @default.
• W2022973635 hasAuthorship W2022973635A5085462551 @default.
• W2022973635 hasBestOaLocation W20229736352 @default.
• W2022973635 hasConcept C126322002 @default.
• W2022973635 hasConcept C141071460 @default.
• W2022973635 hasConcept C2776256026 @default.
• W2022973635 hasConcept C2776694085 @default.
• W2022973635 hasConcept C2777063308 @default.
• W2022973635 hasConcept C2777506904 @default.
• W2022973635 hasConcept C2778119113 @default.
• W2022973635 hasConcept C2778336483 @default.
• W2022973635 hasConcept C2778822529 @default.
• W2022973635 hasConcept C2778850193 @default.
• W2022973635 hasConcept C2780376820 @default.
• W2022973635 hasConcept C2780775027 @default.
• W2022973635 hasConcept C2781190966 @default.
• W2022973635 hasConcept C2781413609 @default.
• W2022973635 hasConcept C71924100 @default.
• W2022973635 hasConcept C90924648 @default.
• W2022973635 hasConceptScore W2022973635C126322002 @default.
• W2022973635 hasConceptScore W2022973635C141071460 @default.
• W2022973635 hasConceptScore W2022973635C2776256026 @default.
• W2022973635 hasConceptScore W2022973635C2776694085 @default.
• W2022973635 hasConceptScore W2022973635C2777063308 @default.
• W2022973635 hasConceptScore W2022973635C2777506904 @default.
• W2022973635 hasConceptScore W2022973635C2778119113 @default.
• W2022973635 hasConceptScore W2022973635C2778336483 @default.
• W2022973635 hasConceptScore W2022973635C2778822529 @default.
• W2022973635 hasConceptScore W2022973635C2778850193 @default.
• W2022973635 hasConceptScore W2022973635C2780376820 @default.
• W2022973635 hasConceptScore W2022973635C2780775027 @default.
• W2022973635 hasConceptScore W2022973635C2781190966 @default.
• W2022973635 hasConceptScore W2022973635C2781413609 @default.
• W2022973635 hasConceptScore W2022973635C71924100 @default.
• W2022973635 hasConceptScore W2022973635C90924648 @default.
• W2022973635 hasIssue "5" @default.
• W2022973635 hasLocation W20229736351 @default.
• W2022973635 hasLocation W20229736352 @default.
• W2022973635 hasLocation W20229736353 @default.
• W2022973635 hasLocation W20229736354 @default.
• W2022973635 hasOpenAccess W2022973635 @default.
• W2022973635 hasPrimaryLocation W20229736351 @default.
• W2022973635 hasRelatedWork W1953499160 @default.
• W2022973635 hasRelatedWork W1990777236 @default.
• W2022973635 hasRelatedWork W2022973635 @default.
• W2022973635 hasRelatedWork W2062530500 @default.
• W2022973635 hasRelatedWork W2088035700 @default.
• W2022973635 hasRelatedWork W2133332025 @default.
• W2022973635 hasRelatedWork W2141429974 @default.

• next